Results 201 to 210 of about 316,809 (303)
Endoscopic small bowel therapies for type 2 diabetes
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel +4 more
wiley +1 more source
The Association Between Serum <i>α</i>1-Acid Glycoprotein and Obesity and Abdominal Obesity in Women: A Cross-Sectional Study Based on NHANES Data From 2015 to 2018. [PDF]
Sun L +5 more
europepmc +1 more source
ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley +1 more source
Combined acupuncture and herb treatment improves intestinal flora inabdominally obese subjects based on 16s rRNA sequencing: a randomized controlled trial. [PDF]
Menghua Y +4 more
europepmc +1 more source
Epidemiology of Abdominal Obesity
Olinto, Maria Teresa Anselmo +2 more
openaire +3 more sources
ABSTRACT Objective Antiobesity medications (AOMs) are indicated for long‐term use; however, evidence of their real‐world long‐term efficacy is limited. This study describes clinical outcomes from 18‐ and 24‐month use of AOMs in a telemedicine weight management clinic.
Kathleen R. Ruddiman +7 more
wiley +1 more source
Anterior to posterior preoperative risk assessment of abdominal thickness compared to BMI in ventral hernias. [PDF]
Brosnihan PJ +6 more
europepmc +1 more source
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone +3 more
wiley +1 more source
Association between different metabolic obesity phenotypes and hyperuricemia: the modifying role of liver enzymes. [PDF]
Guo Z +8 more
europepmc +1 more source
Children with non‐overweight combined with metabolic risk factors might increase the risk of non‐alcoholic fatty liver disease (NAFLD). These findings suggest that overweight and obesity should not be the sole criterion for NAFLD screening in children. In particular, more attention should be given to non‐overweight combined with metabolic abnormalities
Peiyu Ye +22 more
wiley +1 more source

